ライフサイエンスコーパス: cost saving

1 tly dominated treatment with diuretics only (cost-saving).

2 useholds (including both direct and indirect cost savings).

3 population level, upfront genotyping seemed cost saving.

4 tment was significantly effective, safe, and cost saving.

5 s did not indicate that the questionnaire is cost saving.

6 for pregnant women in the UK is potentially cost saving.

7 at the high-dose vaccine is 93% likely to be cost saving.

8 vity analysis showed 79% of simulations were cost saving.

9 sles and rubella eradication is feasible and cost saving.

10 act of telemedicine in the ICU and potential cost saving.

11 P screening and treatment program was highly cost-saving.

12 stage 2 hypertension could be effective and cost-saving.

13 sing scenarios, allopurinol-only therapy was cost-saving.

14 esulted in the full-adherence scenario being cost-saving.

15 campaigns with as much as 70% coverage were cost-saving.

16 hen the test cost was <$100, genotype became cost-saving.

17 oritized PrEP, while risk prioritization was cost-saving.

18 Strategies to reduce shocks could result in cost savings.

19 ce was associated with improved survival and cost savings.

20 , shorter hospitalization, and a significant cost savings.

21 uses annually, which would result in overall cost savings.

22 could improve outcomes and produce long-term cost savings.

23 gh patient satisfaction, and, in some cases, cost savings.

24 s use 450 mg/day due to reported success and cost savings.

25 bioanalytical procedures providing time and cost savings.

26 mproved patient outcomes, and pharmaceutical cost savings.

27 eserve sensitivity, resulting in significant cost savings.

28 of children with IF and was associated with cost savings.

29 y lead to less overtreatment of patients and cost savings.

30 and stopping CD4 monitoring will have major cost savings.

31 e, effective, and contributed to significant cost savings.

32 examinations, which resulted in substantial cost savings.

33 s, SOF/SMV remained dominant and resulted in cost savings.

34 l initial response and result in significant cost savings.

35 hospital discharge could lead to substantial cost savings.

36 There was no evidence for overall cost savings.

37 sons undergoing the procedure rather than on cost savings.

38 metrics in strategies for risk reduction and cost savings.

39 ult in the potential for fall reduction, and cost savings.

40 cancer with consequent potential health care cost savings.

41 ting readmission for quality improvement and cost savings.

42 are carbon emissions, water withdrawal, and cost savings.

43 erms of lesser intervention of operators and cost savings.

44 of the human genome at high-speed and large cost savings.

45 cost of avoided CO2e at $16-29 and household cost savings.

46 frequently viewed as a potential source for cost savings.

47 safely reduces hospital LOS with significant cost savings.

48 ed with their care can result in substantial cost savings.

49 antial improvements in clinical outcomes and cost savings.

50 ve complications could result in substantial cost savings.

51 s estimated to have resulted in $8,108.84 of cost savings.

52 ing while bringing significant computational cost savings.

53 care use and disability, resulting in major cost savings.

54 important for future disease management and cost savings.

55 t in high-temperature systems for energy and cost savings.

56 erall, LT does not provide glaucoma-specific cost savings.

57 have the potential to result in significant cost savings.

58 unusual ingredients and thus help to achieve cost-savings.

59 in the ACEI+BB+AldA arm resulted in greater cost-savings.

60 highly cost-effective and may even result in cost-savings.

61 ch hospital could achieve an equal amount of cost savings ($44 804/y).

62 25% home dialysis), FHNHD led to incremental cost savings (-$6700) and an additional 0.38 QALYs.

63 ased length of stay with CCTA and 3 reported cost savings; 8.4% of patients undergoing CCTA versus 6.

64 improvements in wellbeing-rather than merely cost savings-again depends on the ethical approach to va

65 ipping conditions and opens a new avenue for cost-saving ambient-temperature DBS specimen shipments f

66 that the intervention resulted in both a net cost savings and a net increase in QALYs.

67 afforded significant advantages in terms of cost savings and adverse events averted compared with IV

68 iver sizeable health gains and health sector cost savings and are likely to reduce health inequalitie

69 hese findings may result in potential health cost savings and eliminate perioperative risks related t

70 e potentially offering other benefits (e.g., cost savings and environmental impact reduction).

71 bsidies and incentives that do not encourage cost savings and good performance, insurance policies th

72 c substitutions result in minimal additional cost savings and have an inherent risk of medication err

73 teredness but also to find opportunities for cost savings and increased efficiencies.

74 HIV-infected patients would result in modest cost savings and likely reduce patient anxiety, with lit

75 blished hospitalization data to estimate the cost savings and number of hospitalizations that could b

76 rting with short oligos remain important for cost savings and pedagogical benefit.

77 ay discharge was associated with significant cost savings and was preferred by patients.

78 itivity Analysis: Individualized control was cost-saving and generated more QALYs compared with unifo

79 Screening using bead-based assay is cost-saving and improves graft outcomes.

80 ombined with linkage to addiction treatment (cost saving), and naloxone distribution combined with Pr

81 nt is highly beneficial for quality of life, cost saving, and cost-effectiveness in the United States

82 reduction in delay to treatment, health care cost savings, and decrease in no-show rate.

83 s the only strategy that resulted in patient cost savings, and was the most favorable strategy in ter

84 be tailored for cultural competence, can be cost-saving, and can help to address the unmet needs of

85 ing prevents inappropriate HIV diagnosis, is cost-saving, and should be adopted in all EID programmes

86 ction in the force, result in a small system costs savings, and decrease the threat of transfusion-tr

87 vider satisfaction, quality improvement, and cost savings; and ensuring sustainability through adequa

88 tests together with the concept of time and cost saving are pushing the development of portable, min

89 0,879-US$1.6 million) per year; 80% of these cost savings are due to reductions in benefit payments a

90 Most cost savings are expected to accrue to Medicare, and mos

91 that includes only direct medical costs, the cost savings are S$144 per person.

92 The greatest benefits and cost-savings are achieved if transplantation occurs at a

93 high-throughput applications, the potential cost savings associated with 3'-DGE approach are likely

94 are polyclinics, the present value of future cost savings associated with the telemedicine-based mode

95 illance biopsy reduces the average simulated cost savings at 10 years by $4951 per patient.

96 nnish Asthma Program resulted in significant cost savings at both the societal and patient levels dur

97 We also estimate the cost savings attributable to the pneumonia prevention pr

98 for mental health care may lead not only to cost savings but also to negative downstream consequence

99 All other strategies resulted in payer cost savings but were less efficacious.

100 ing patients with existing CNV in one eye is cost saving, but monitoring is generally not cost-effect

101 rm such functions can be advantageous due to cost savings, but when they are essential for growth, or

102 waZulu-Natal could be very cost-effective or cost-saving, but suboptimal PrEP would erode benefits an

103 The program generates potential cost savings by reducing the historic cost of time-defin

104 Significant cost savings can be realized through careful and efficie

105 hough our findings suggest the potential for cost savings, changes in payment policy for CAHs could d

106 An antiviral prophylaxis strategy was cost saving compared to the current strategy and should

107 tion plus linkage to addiction treatment was cost saving compared with no additional intervention (gr

108 bined with linkage to addiction treatment is cost saving compared with no additional services.

109 The model predicts Aprokam is cost saving compared with purchased PFS, with a modest i

110 a catch-up campaign of 1- to 4-year-olds is cost saving compared with the reactive strategy, both wi

111 in absenteeism and benefit payments lead to cost savings compared to a scenario of no treatment prov

112 is, it provided superior health outcomes at cost savings compared to the pretransplant DAA treatment

113 Pharmacy purchasing data underestimated cost savings compared with EMR and PHIS data, while EMR

114 Shorter length of stay and cost savings compared with national data were observed a

115 s is not only more accurate than but is also cost-saving compared to conventional culture methods.

116 bers reduces savings but is still marginally cost-saving compared to no treatment.

117 Allopurinol single therapy is cost-saving compared with no treatment.

118 VL failure confirmation was cost-saving compared with SOC.

119 both standard PrEP and long-acting PrEP were cost saving, compared with no PrEP.

120 acceptable among individuals and could allow cost savings, compared with provider-delivered HIV testi

121 esearch demonstrates significant health care cost savings conferred by allergen-specific immunotherap

122 n a high-wind scenario, resulting in a 6-20% cost savings, depending on the avoided conventional tech

123 vaccine (8.1499 QALYs [0.5697]) and, due to cost savings, dominated standard-dose vaccine in the cos

124 Univariate sensitivity analyses demonstrated cost-savings down to a PF rate of 5.6%, up to a relative

125 Cost savings due to a lower risk of hospitalization for

126 Future antiretroviral treatment (ART) cost savings during the lifetime of the cohort exposed t

127 roke network was associated with $358 435 in cost savings; each spoke had $109 080 in cost savings, w

128 Polypill patients commented frequently on cost-savings, ease, and convenience of a daily-dosing pi

129 es for recombineering, including significant cost savings, especially for high-throughput projects th

130 wet season, malaria preventive treatment was cost saving even when average daily bed-stay costs were

131 without cardiovascular disease would remain cost-saving even if strategies to increase medication ad

132 The QUENCHER method is a time and cost-saving extraction-free procedure measuring in vitro

133 ccination, and the vaccine interventions are cost saving for all age and risk groups.

134 cts of patients with Ebola virus disease was cost saving for contacts of all ages in Liberia, Sierra

135 lecular steps in conventional methods and is cost saving for parasite populations >50.

136 ary, redistricting appears to be potentially cost saving for the health care system but will increase

137 The theoretical total cost savings for 2013, comparing actual with predicted c

138 entially significant sources of bed days and cost savings for hospitals and the healthcare system ove

139 costs and, in India and China, produced net cost savings for most interventions under a societal per

140 Biosimilars promise significant cost savings for patients, but the unavoidable differenc

141 gal isolates, it also provides a significant cost savings for the laboratory.

142 centres, as well as bringing convenience and cost savings for the patient and service provider.

143 Workplace ART provision can be cost-saving for companies in high HIV prevalence setting

144 etary expenditures for the government but is cost-saving for patients at high risk of AMD.

145 ecrease with decreasing DAA prices, becoming cost-saving for the base price (euro15,000) discounts of

146 Iodine supplementation was cost saving from both a health service perspective (savi

147 regimens is likely to result in significant cost savings from a societal perspective, relative to no

148 Net cost savings from fall prevention was estimated.

149 ART has resulted in substantial cost savings from OIs averted.

150 osimulation model, we explored the potential cost savings from the hospital system perspective under

151 e ezetimibe becomes generic, and may lead to cost savings from the perspective of the healthcare syst

152 The present value of total lifetime cost savings from the policy change is estimated to be U

153 decisions may have reduced the potential for cost savings from water quality trading and payment prog

154 Net cost savings generated in our example scenario, with 900

155 Among MSM in San Diego, EarlyTest was cost-savings (ie, ICERs per AHI diagnosis less than $13.

156 has been cost effective, and is likely to be cost saving if a commitment is made to provide ART to al

157 io was less than three times the GDP, and as cost-saving if it resulted in a decrease in total costs

158 ensitivity and scenario analyses, and it was cost-saving if it resulted in fewer overdoses or emergen

159 3, sofosbuvir-ledipasvir-ribavirin would be cost-saving if sofosbuvir cost less than $1500 per week.

160 enotype 2, sofosbuvir-ribavirin-PEG would be cost-saving if sofosbuvir cost less than $2250 per week.

161 most simulations for genotype 1 and would be cost-saving if sofosbuvir cost less than $5500.

162 Routine pediatric EV71 vaccination would be cost-saving if the all-inclusive EVC is below US$10.6 (9

163 MC is cost effective and potentially cost saving in both the United States and Africa.

164 egies using MenAfriVac will be significantly cost saving in Burkina Faso, both for the health system

165 pyramid, the intervention is expected to be cost saving in contacts of all age groups in areas with

166 It was cost saving in patients with HIV, homelessness, or subst

167 f lower measurement variability, CMR is more cost saving in pulmonary arterial hypertension drug tria

168 the ICU is cost-effective in most cases and cost saving in some cases.

169 for secondary prevention was projected to be cost saving in the main simulation and 100% of probabili

170 dren in LMICs, and estimated large potential cost savings in OIs averted with ART use, although there

171 n goals, potentially generating programmatic cost savings in settings with high precontrol endemicity

172 Service costs were compared to cost savings in terms of rates of criminal re-offending.

173 Annual health care cost savings in the United States ranging from $6 to $30

174 a or alpha 2b plus ribavirin was dominant or cost-saving in Thailand compared to a palliative care.

175 MSM in the UK is cost-effective and possibly cost-saving in the long term.

176 The cost-savings in the ACEI and ACEI+BB cohorts compared to

177 might be cost-effective far sooner, and even cost-saving, in settings where long-term health-care cos

178 We discuss the relative impacts of both cost-savings information and environmental health messag

179 Currently available standard PrEP is a cost-saving intervention whose delivery should be expand

180 These probabilistic analyses projected that cost saving is achieved 37% of 1,000 iterations.

181 Cost saving is also feasible if the per-patient per-hosp

182 The qHPV vaccination strategy was cost saving; it decreased lifetime costs by $419 and inc

183 re, growing use of technology, and potential cost savings makes developing and incorporating palliati

184 cal RO-HER plant cost suggesting significant cost savings may also be realized.

185 Additionally, these cost savings may be most prominent amongst the patients

186 for the detection of sequence variants as a cost saving measure.

187 ficiaries with glaucoma reported engaging in cost-saving measures.

188 self-taken samples could be an effective and cost-saving method, with high negative predictive values

189 mplementation has the potential for dramatic cost savings nationally, further studies assessing overa

190 generally cost more than no MTD, incremental cost savings occurred in patients with human immunodefic

191 cost-saving to cost-effective, with maximum cost savings occurring when a hospital uses more expensi

192 2 with proton pump inhibitor, resulting in a cost saving of $1,095 with histamine receptor-2 antagoni

193 ual rates of C. difficile infection showed a cost saving of $908 with histamine receptor-2 antagonist

194 s of 2.8k (SD, 14.5k) per patient and an ICU cost saving of 25%.

195 imus borneensis), and achieve an opportunity cost saving of over US$43 billion.

196 stroke patients, the model produces a total cost saving of pound5.2 million per year at 90 days (95%

197 The second aim was to examine potential cost saving of telemedicine in the ICU through probabili

198 TC yielded cost savings of $114 per patient.

199 stay by 1.6 days (P = 0.002), and a hospital cost savings of $1492 per patient (P = 0.01).

200 symptomatic horseshoe tear resulted in a net cost savings of $1749 ($1314) and improved utility, wher

201 hourly periods could have provided a health cost savings of $175.9 million dollars for an additional

202 cost-effective, based on the estimated labor cost savings of $2,132.71 for each percent increase in t

203 dstream infection, for an approximate annual cost savings of $2.34 million.

204 This resulted in cost savings of $20.28 per patient, reduction of wait ti

205 of stay reductions resulted in an estimated cost savings of $3202 per patient (2011) and $4803 per p

206 This resulted in cost savings of $35.68 per patient, shortened wait-time

207 idence interval [CI], 828 032-874 853), with cost savings of $46.7 million (95% CI, $43.8-$49.4 milli

208 tient-days, respectively, for a total yearly cost savings of $54656 for pharmacy purchasing data, $11

209 LBHs and MBHs resulted in significantly more cost savings of $9155 per HBH patient, or $699 per patie

210 oth interventions could have resulted in ICU cost savings of 1.9 billion, representing a 6% reduction

211 Column reuse resulted in cost savings of 21,458 USD per patient.

212 less-expensive treatment option could yield cost savings of 40% to 88%.

213 s appointment, there would be an incremental cost savings of A$5461 (US$4140) (95% CI, A$1433-A$10557

214 iary presentation resulted in an incremental cost savings of A$9020 (US$6838) per additional diagnosi

215 ural land is included as an option, Bay-wide cost savings of about 60% could be realized compared to

216 erm births averted and total annual economic cost savings of about US$3 billion.

217 61 000 OIs (2013 UNAIDS data) with estimated cost savings of at least US$17 million per year.

218 300 (95% CI: 68,700; 277,800) and healthcare cost savings of AU$1,733 million (m) (95% CI: $650m; $2,

219 The estimated annualized labor cost savings of culture using blood culture bottles was

220 At a disease prevalence of 75%, per-patient cost savings of empirical terbinafine therapy without co

221 se model (A) in which we estimated the total cost savings of intervention effects and a conservative

222 imately 6118 prevented pneumonia cases and a cost savings of more than $280 million.

223 Annual cost savings of pound5.5 to pound8.2 million ($7.3-$10.9

224 Additional analysis determined potential cost savings of quality improvement programs to reduce S

225 de it imperative to understand the potential cost savings of quality-improvement initiatives.

226 g model had significantly lower costs (total cost savings of S$173 per person) while generating simil

227 xtra 6.4 and 6.1 grafts would be saved, with cost savings of U.S. $867,203 and U.S. $830,664 per 100

228 In Uganda, cost savings of up to 62% were observed with a centraliz

229 We estimated cost savings on the basis of reported costs for preterm

230 naive to treatment with biologicals, and is cost saving over 12 months.

231 yr or 9.8 mo) but also leads to incremental cost savings over a lifetime projection of pound1,285.77

232 SB seems to offer a modest cost savings over PPV for repair of RRD in phakic patien

233 In South Africa, early ART was cost-saving over a 5-year period.

234 ART prevented opportunistic diseases and was cost-saving over a 5-year period; over a lifetime, it wa

235 There was a cost saving per case of A$633,446 in 2010-2011 compared

236 udy cohort ranged from euro14903 (France) to cost saving (Poland).

237 nd of the 15th year, would result in a total cost saving ( pound1.0 billion discounted), avert 25% of

238 oring), goal-directed therapy still achieved cost savings ( pound471.70).

239 dology benefits from reagent-free, time- and cost-saving procedure, due to most efficient solid-phase

240 the most from this effective and potentially cost-saving public health intervention.

241 The magnitude of 18-month health care cost savings realized by AIT-treated adults and children

242 Cost abatement curves display per unit cost savings related to overall direct and indirect ener

243 ieving an estimated 32.1% (95% CI 29.6-34.5) cost saving relative to adopting country-wide policies.

244 proach produces substantial benefits and net cost savings relative to the status quo.

245 benefits relating to improved efficiency and cost-savings remain elusive due to a lack of system matu

246 As cost-saving results, the Subcommittee for Development of

247 Cost-saving short (50-bp) single-end reads and Nextera (

248 ce development and provided an effective and cost-saving strategy for patients having HBV-related LT.

249 epositioning is considered to be a time- and cost-saving strategy to assess drugs already licensed fo

250 A cost-saving strategy to diagnose other diseases is to po

251 qHPV vaccine after treatment for HGAIN is a cost-saving strategy.

252 tment, providing greater health benefits and cost savings than the observed standard of care.

253 Given the substantial cost savings that ASA24 offers, it has the potential to

254 otal maximum daily load (TMDL) and potential cost savings that could be realized by a more efficient

255 To identify the mechanisms of potential cost savings, the frequency and amount of physician, rea

256 5) What strategies can be used to promote cost savings through greater generic medication use?

257 could be considered cost-effective at $149 (cost saving to $387) per DALY averted.

258 Monitoring could be cost saving to society if monitoring reduced the frequen

259 It also indicates potential cost saving to the nonodorous and scope for personalized

260 cost-effectiveness ratio of $35663 (95% CI, cost savings to $235613) per quality-adjusted life-year

261 EP) would substantially shorten the time for cost savings to be realised.

262 Cost savings to both patients and the facility were sign

263 clinics increased dramatically, neutralizing cost savings to Medicare and highlighting the possible u

264 Cost savings to payers and patients were seen for most r

265 decolonization, universal decolonization is cost-saving to cost-effective, with maximum cost savings

266 over the current reimbursement system, true cost-savings to Medicare will be realized only when the

267 Outpatient treatment allows important costs saving to the health systems without negative infl

268 ide 95% CI from a negative value (suggesting cost savings) to $375,870.

269 lication of the NICE guidance, which assumed cost savings, to participants with CKD G3aA1 increased t

270 QALY gains and cost savings took 50 y to peak, owing to such factors as

271 cCTA may be a cost-saving tool in acute chest pain populations that ha

272 ART in truly HIV-uninfected infants, it was cost-saving: total cost US$1,790/infant tested, compared

273 Estimated cost savings totaled $2.5M during the 2-year interventio

274 aintenance or 2-drug for ART-naive patients, cost savings totaled $550 million and $800 million, resp

275 Pasireotide appears to be a cost-saving treatment following PD across a wide variati

276 Kidney transplantation is a cost-saving treatment that extends the lives of patients

277 regarding incidence and absenteeism, ART is cost-saving under considerable parameter uncertainty and

278 Confirmatory testing remained cost-saving unless NAAT cost exceeded US$400 or the HIV-

279 that comprehensive care was cost neutral or cost saving was 97%.

280 The average monthly asthma-related cost savings was $34.02/mo (95% CI, $5.42/mo to $61.24/m

281 Institutional cost savings was estimated at $27000 per year.

282 Cost savings was more prominent amongst high-risk patien

283 Furthermore, a positive institutional cost savings was observed.

284 were employed to determine significance, and cost savings were estimated based on our internal costs.

285 tobacco tax increases, compared to BAU, and cost savings were US$2,550 million (95% UI: US$1,480 to

286 pport the finding that MST+YOT has scope for cost-savings when compared to YOT alone.

287 in cost savings; each spoke had $109 080 in cost savings, whereas the hub had positive costs of $405

288 eumatic retinopexy would achieve significant cost savings while maintaining outcomes.

289 s hospitalized for more than 3 days and in a cost savings while retaining the ability of the clinicia

290 massive methane resource, and the potential cost savings while sequestering a greenhouse gas, keeps

291 undue focus on administrative efficiency and cost savings will not necessarily guarantee cutting-edge

292 FQN therapy remained cost saving with improved outcomes even if the effective

293 Our data strongly suggest potential cost savings with fondaparinux and underscore the critic

294 Median cost savings with IAD was estimated to be 48%.

295 in the United States to determine potential cost savings with pneumatic retinopexy.

296 was associated with a lower rate of MACE and cost savings, with a threshold effect at >80% adherence

297 e greatest impact on TB incidence and became cost-saving within 5 years if delivered at $10/test.

298 ffice-based setting could yield considerable cost savings without adversely affecting health outcomes

299 ignificant reductions in ICU albumin use and cost savings without changes in patient outcomes, suppor

300 in the patients without ICD indications, the cost savings would be $1.6 million.